Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Tandem Diabetes Care (TNDM) over the last 13 years, with Q3 2025 value amounting to $115.0 million.

  • Tandem Diabetes Care's Cost of Revenue fell 365.16% to $115.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $471.0 million, marking a year-over-year increase of 980.45%. This contributed to the annual value of $450.6 million for FY2024, which is 1857.78% up from last year.
  • As of Q3 2025, Tandem Diabetes Care's Cost of Revenue stood at $115.0 million, which was down 365.16% from $114.8 million recorded in Q2 2025.
  • Tandem Diabetes Care's 5-year Cost of Revenue high stood at $125.2 million for Q4 2024, and its period low was $67.8 million during Q1 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $98.3 million (2022), whereas its average is $99.5 million.
  • In the last 5 years, Tandem Diabetes Care's Cost of Revenue skyrocketed by 4528.86% in 2021 and then plummeted by 424.78% in 2023.
  • Tandem Diabetes Care's Cost of Revenue (Quarter) stood at $96.3 million in 2021, then grew by 9.05% to $105.0 million in 2022, then dropped by 1.41% to $103.5 million in 2023, then grew by 20.96% to $125.2 million in 2024, then fell by 8.17% to $115.0 million in 2025.
  • Its Cost of Revenue stands at $115.0 million for Q3 2025, versus $114.8 million for Q2 2025 and $116.0 million for Q1 2025.